- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07664085
High-Flow Nasal Cannula After Extubation in Acute Brain Injury
High-Flow Nasal Cannula Versus Conventional Oxygen Therapy After Extubation in Mechanically Ventilated Patients With Acute Brain Injury: A Propensity-Score Overlap-Weighted Observational Cohort Study
Patients with acute brain injury after neurosurgery are at increased risk of extubation failure after removal of the endotracheal tube. High-flow nasal cannula (HFNC) may provide better post-extubation respiratory support than conventional oxygen therapy (COT), but evidence in post-neurosurgical patients remains limited.
This prospective observational study evaluated adult post-neurosurgical patients with acute brain injury who underwent planned extubation in the Surgical Intensive Care Unit of Bach Mai Hospital, Vietnam. Patients received either HFNC or COT after extubation according to routine clinical practice and the decision of the attending ICU physicians. The primary outcome was treatment failure, defined as reintubation or escalation of respiratory support within 5 days after extubation. Secondary outcomes included tracheostomy, ventilator-associated pneumonia, ICU length of stay, total duration of mechanical ventilation, and time from extubation to reintubation. Propensity score matching was used to reduce baseline imbalance between groups.
Studieoversigt
Status
Detaljeret beskrivelse
Extubation failure is a clinically important complication in patients with acute brain injury after neurosurgery. These patients may have impaired consciousness, weak cough, reduced airway protection, and limited respiratory reserve, which can increase the risk of reintubation and other postoperative pulmonary complications. High-flow nasal cannula provides heated and humidified oxygen at high flow rates and may improve oxygenation, reduce work of breathing, and support airway clearance after extubation.
This study was designed as a prospective observational cohort study conducted in the Surgical Intensive Care Unit of Bach Mai Hospital. Adult patients aged 16 years or older who were admitted after neurosurgery for acute brain injury, required invasive mechanical ventilation for at least 24 hours, successfully completed a spontaneous breathing trial, had adequate airway protection, and underwent planned extubation were consecutively enrolled. The choice of post-extubation oxygen therapy was not assigned by the investigators. Patients received either HFNC or conventional oxygen therapy according to the attending ICU physician's clinical decision and routine ICU practice.
In the HFNC group, HFNC was initiated immediately after planned extubation when selected by the treating physician. The initial flow rate was 60 L/min, and FiO2 was titrated to maintain SpO2 between 95% and 100%. HFNC was planned for at least the first 24 hours after extubation and was subsequently weaned according to clinical tolerance. In the conventional oxygen therapy group, oxygen was delivered through a standard nasal cannula or face mask, with oxygen flow adjusted to maintain the same SpO2 target.
Clinical data, respiratory parameters, neurological status, arterial blood gas results, oxygen therapy settings, escalation of respiratory support, reintubation, tracheostomy, ventilator-associated pneumonia, duration of mechanical ventilation, and ICU length of stay were collected from ICU medical records, bedside monitoring charts, and nursing or respiratory therapy documentation.
The primary outcome was treatment failure, defined as reintubation or escalation of respiratory support within 5 days after extubation. Secondary outcomes included tracheostomy during ICU stay, ventilator-associated pneumonia, ICU length of stay, total duration of mechanical ventilation, and time from extubation to reintubation. Propensity score matching was performed to reduce selection bias between the HFNC and conventional oxygen therapy groups. Matching variables included age, sex, body mass index, diagnosis category, Glasgow Coma Scale score, airway protection status, duration of mechanical ventilation, and baseline gas exchange variables.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Hanoi
-
Hanoi, Hanoi, Vietnam, 00000
- Bach Mai Hospital, Hanoi, Viet Nam.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients aged 16 years or older.
- Admission to the Surgical Intensive Care Unit after neurosurgery for acute brain injury, including traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke, or other acute neurosurgical brain conditions.
- Requirement for invasive mechanical ventilation for at least 24 hours.
- Undergoing planned extubation after clinical assessment by the treating ICU team.
- Successful completion of a spontaneous breathing trial lasting 30 to 120 minutes.
- Adequate airway protection, defined as an Airway Care Score less than 8 points.
- Neurological readiness for extubation, as assessed by Glasgow Coma Scale score and bedside neurological examination.
- Adequate oxygenation before extubation, including PaO2/FiO2 greater than 200 mmHg and PEEP less than 7 cmH2O.
Exclusion Criteria:
- Pre-existing tracheostomy.
- Known upper airway obstruction, including airway stenosis or airway tumor.
- Suspected cerebrospinal fluid leak or complex skull base fracture.
- Unplanned self-extubation.
- Requirement for immediate prophylactic reintubation before initiation of post-extubation oxygen therapy.
- Requirement for non-invasive ventilation before initiation of the study exposure.
- Missing key clinical data required for outcome assessment or propensity score matching.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
High-Flow Nasal Cannula Group
Patients who received high-flow nasal cannula immediately after planned extubation according to routine clinical practice and the attending ICU physician's decision.
HFNC was initiated after extubation with an initial flow rate of 60 L/min, and FiO2 was titrated to maintain SpO2 between 95% and 100%.
HFNC was planned to continue for at least the first 24 hours after extubation and was then weaned according to clinical tolerance.
|
|
Conventional Oxygen Therapy Group
Patients who received conventional oxygen therapy after planned extubation according to routine clinical practice and the attending ICU physician's decision.
Oxygen was delivered via a standard nasal cannula or face mask, with oxygen flow adjusted to maintain SpO2 between 95% and 100%.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients with treatment failure within 5 days after planned extubation
Tidsramme: Within 5 days after planned extubation
|
Treatment failure was defined as reintubation or escalation of respiratory support after planned extubation.
Escalation of respiratory support included the need for non-invasive ventilation, rescue high-flow nasal cannula therapy in the conventional oxygen therapy group, or other clinically indicated escalation due to respiratory deterioration.
Outcome assessment was based on bedside clinical monitoring, arterial blood gas analysis, respiratory status, neurological status, airway protection assessment, and ICU medical record review.
|
Within 5 days after planned extubation
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients requiring tracheostomy during ICU stay
Tidsramme: From planned extubation through ICU discharge, assessed up to 30 days after planned extubation
|
The proportion of patients who required tracheostomy after planned extubation.
Tracheostomy was identified by review of ICU medical records, operative or procedure notes, and hospital documentation.
|
From planned extubation through ICU discharge, assessed up to 30 days after planned extubation
|
|
Incidence of ventilator-associated pneumonia during ICU stay
Tidsramme: From planned extubation through ICU discharge, assessed up to 30 days after planned extubation
|
Ventilator-associated pneumonia was assessed by review of hospital medical records using predefined clinical, radiographic, and microbiological criteria, including clinical examination, chest radiograph findings, and microbiological culture results.
|
From planned extubation through ICU discharge, assessed up to 30 days after planned extubation
|
|
Length of stay in the intensive care unit
Tidsramme: From ICU admission through ICU discharge, assessed up to 30 days after ICU admission
|
ICU length of stay was calculated using the recorded dates and times of ICU admission and ICU discharge from ICU charts and hospital medical records.
|
From ICU admission through ICU discharge, assessed up to 30 days after ICU admission
|
|
Time from planned extubation to reintubation
Tidsramme: From planned extubation through reintubation, assessed up to 5 days after planned extubation
|
Time from planned extubation to reintubation was calculated from the recorded date and time of extubation to the recorded date and time of re-insertion of the endotracheal tube.
Patients who were not reintubated were censored at 5 days after extubation.
|
From planned extubation through reintubation, assessed up to 5 days after planned extubation
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BM_2024_231
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data underlying the main study results may be shared after publication of the primary results. Data sharing will be considered for researchers conducting systematic reviews, meta-analyses, or methodologically sound secondary analyses. Access will require approval by an ethics committee and a signed data sharing agreement with the study custodian or sponsor.
Supporting Information:
Study Protocol, Statistical Analysis Plan, Analytic Code, Informed Consent Form
Time Frame:
Beginning after publication of the main study results; end date not yet determined.
Access Criteria:
Requests may be submitted by qualified researchers for systematic reviews, meta-analyses, or approved secondary analyses. Data access will require ethics committee approval, a scientifically valid proposal, and completion of a data sharing agreement. Shared data will be de-identified.
URL:
Leave blank if there is no public repository.
Email / Contact:
haigmhshmu@gmail.com
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut hjerneskade
-
Virginia Polytechnic Institute and State UniversityTrukket tilbage
-
University of MinnesotaRekruttering
-
Assistance Publique Hopitaux De MarseilleUkendt
-
BraindexClinique de la SauvegardeAfsluttetAnæstesi | Brain MonitorFrankrig
-
National Institute of Mental Health (NIMH)AfsluttetKÆLEDYR | Brain Imaging | Cannabinoid | CB1Forenede Stater
-
GE HealthcareAfsluttetBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Mayo ClinicAfsluttetBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Truway Health, Inc.Tilmelding efter invitationEvaluering af In-Vitro Cryo Terapeutiske Protokoller på Humane Celleprøver (TWH-CRYO-001) (CRYO-IVT)Cellular Injury and Post-Cryogenic Recovery | Kryogenisk cellulær stress | Kuldeinduceret cellulær skade | Termisk Skade Reaktion | Post-thaw levedygtighedsforringelse | Osmotisk Stressskade | Biomekanisk Skadesmodellering (In-Vitro) | Blunt Force Injuries to the Extremities (Cellular Injury Model) | Vævsskade... og andre forholdForenede Stater
-
Hospital Universitari Son DuretaEspen; This research prize was funded by Nestle Nutrition Institute and...AfsluttetModerat til alvorligt traume, som defineret af en | Injury Severity Score (ISS) > 12 point var inkluderet i undersøgelsen.Spanien
-
Tang-Du HospitalIkke rekrutterer endnuPsykisk lidelse | Sociale medier | Brain Imaging